This week’s View offers key points from an article about the mechanism, use, and future of proprotein convertase subtilisin/kexin type 9 inhibitors.

Subscribe on iTunes | Subscribe on Google Play

Keywords: EaglesEyeView, Acute Coronary Syndrome, Atherosclerosis, Brain Ischemia, Cholesterol, HDL, Cholesterol, LDL, Coronary Artery Disease, Diabetes Mellitus, Type 2, Dyslipidemias, Hydroxymethylglutaryl-CoA Reductase Inhibitors, Hyperlipoproteinemia Type II, Metabolic Syndrome, Myalgia, Myocardial Infarction, Primary Prevention, Plaque, Atherosclerotic, Proprotein Convertases, Receptors, LDL, Stroke, Subtilisins, Triglycerides, Renal Insufficiency, Chronic

< Back to Listings